16/07/2026
๐ ๐๐๐ญ๐๐ง๐ญ ๐๐จ๐ฑ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง๐ฌ ๐๐ฏ๐๐ซ๐ฒ ๐๐
๐ ๐๐ก๐จ๐ฎ๐ฅ๐ ๐๐ฌ๐ค ๐๐จ๐ฐ ๐ข๐ง ๐๐จ๐ง๐ ๐๐จ๐ง๐
A technology-driven client recently asked us a deceptively simple question: โWe know our IP creates value, but how much of our product income can realistically qualify for the concessionary rate?โ
That question is becoming more important, not less.
The latest IRD discussion makes clear that โembedded IP incomeโ under Hong Kongโs patent box regime cannot be approached as a rough commercial estimate. The IRDโs view is that the allocation must be determined in a way that is consistent with OECD Transfer Pricing Guidelines. Even where the IP is unique, self-developed and lacks good comparables, the answer is still expected to come from a transfer pricing methodology that reflects the underlying value creation.
That means this is no longer just a tax incentive issue. It is a tax data, documentation and valuation issue.
For CFOs, the real risk is not simply underclaiming the benefit. It is overclaiming based on internal assumptions that do not stand up to a transfer pricing review. Our commentary underlines that point: the IRD appears willing to accept flexible methodologies, but only where taxpayers can demonstrate that the methodology is genuinely aligned with OECD guidance.
The commercial message is clear. If your group is relying on patent box economics in board discussions, valuation models or tax provisioning, the methodology should be tested before filing season, not after the numbers are locked.
Tax incentives can be powerful. But in practice, many of them become documentation projects in disguise.
If your business has valuable in-house IP and expects Hong Kong tax benefits from it, this is the time to align tax, finance and transfer pricing teams.